Format

Send to

Choose Destination
Indian J Surg Oncol. 2019 Jun;10(2):342-349. doi: 10.1007/s13193-018-0860-5. Epub 2019 Jan 5.

Uterine Sarcomas: Experience from a Tertiary Cancer Care Center from India.

Author information

1
1Department of Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Road No 10, Banjara Hills, Hyderabad, India.
2
2Present Address: Apollo hospital, Chennai, India.
3
Present Address: American Oncology Institute, Hyderabad, India.
4
4Department of Laboratory Medicine, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India.

Abstract

Uterine sarcomas are uncommon and aggressive tumors comprising 3-7% of all uterine malignancies. The aim is to evaluate clinical presentation, histopathologic pattern, recurrence pattern, and outcome of patients with uterine sarcomas presenting to a tertiary care cancer center over an 8-year period. A total of 11 cases of uterine sarcoma were diagnosed. The median age of patients at presentation was 51 years (range 30-67 years). Six patients had leiomyosarcoma (54.5%), 4 had endometrial stromal sarcoma (36%), and 1 had adenosarcoma (9%). The main presenting symptoms were abnormal vaginal bleeding, low abdominal pain, and white discharge. Median follow-up was 11 months ranging from 3 to 200 months. Median survivals for leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma were 6.5, 18, and 56 months. The 3- and 5-year survival by Kaplan-Meier survival analysis of the entire cohort was 30 and 20%. The mitotic index, age, adjuvant therapy (chemotherapy, radiotherapy), and performance of pelvic nodal dissection did not impact survival significantly in the patient with leiomyosarcoma. Stage and histology had the strongest bearing on survival and leiomyosarcoma has the worst survival, whereas adenosarcoma had the best prognosis. Adequately powered prospective studies are required to define the role of radiation therapy and chemotherapy in this rare disease.

KEYWORDS:

Adenosarcoma; Carcinosarcoma; Endometrial stromal sarcoma; Leiomyosarcoma; Uterine sarcoma

PMID:
31168260
PMCID:
PMC6527712
[Available on 2020-06-01]
DOI:
10.1007/s13193-018-0860-5

Conflict of interest statement

Conflict of InterestThe authors declare that they have no conflict of interest.

Supplemental Content

Loading ...
Support Center